1. Home
  2. FERG vs NTRA Comparison

FERG vs NTRA Comparison

Compare FERG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ferguson plc

FERG

Ferguson plc

HOLD

Current Price

$236.45

Market Cap

47.4B

Sector

Miscellaneous

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$327.72

Market Cap

45.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FERG
NTRA
Founded
1887
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Miscellaneous
Medical Specialities
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.4B
45.3B
IPO Year
2024
2015

Fundamental Metrics

Financial Performance
Metric
FERG
NTRA
Price
$236.45
$327.72
Analyst Decision
Buy
Strong Buy
Analyst Count
13
15
Target Price
$268.54
$259.07
AVG Volume (30 Days)
3.7M
1.4M
Earning Date
06-02-2026
05-07-2026
Dividend Yield
1.39%
N/A
EPS Growth
9.26
0.65
EPS
5.56
N/A
Revenue
$30,762,000,000.00
$210,939,000.00
Revenue This Year
$7.98
$18.08
Revenue Next Year
$5.86
$19.65
P/E Ratio
$43.57
N/A
Revenue Growth
3.80
N/A
52 Week Low
$207.64
$157.43
52 Week High
$271.64
$333.56

Technical Indicators

Market Signals
Indicator
FERG
NTRA
Relative Strength Index (RSI) 45.25 68.06
Support Level $219.86 $187.64
Resistance Level $268.63 N/A
Average True Range (ATR) 6.55 10.93
MACD -1.75 1.95
Stochastic Oscillator 2.87 90.53

Price Performance

Historical Comparison
FERG
NTRA

About FERG Ferguson plc

Ferguson distributes plumbing and HVAC products to North American repair, maintenance, and improvement, new construction, and civil infrastructure markets. It serves over 1 million customers and sources products from 37,000 suppliers. Ferguson engages customers through approximately 1,700 North American branches, over the phone, online, and in residential showrooms. The firm sold its UK business in 2021 and is now solely focused on the North American market.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: